lansoprazole has been researched along with Acute Myelogenous Leukemia in 1 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Concomitant lansoprazole had minimal effect on quizartinib PK as a formulated tablet, indicating that quizartinib can be administered with ARAs." | 2.90 | A drug-drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics. ( Cook, N; Li, J; Mendell, J; O'Donnell, P; Trone, D, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 1 |
| Trone, D | 1 |
| Mendell, J | 1 |
| O'Donnell, P | 1 |
| Cook, N | 1 |
1 trial available for lansoprazole and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
A drug-drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics.
Topics: Adult; Antineoplastic Agents; Benzothiazoles; Dose-Response Relationship, Drug; Drug Interactions; D | 2019 |